What is Axsome Therapeutics's depreciation?

Axsome Therapeutics (AXSM) reported depreciation of $116K in Q1 2026.

How has Axsome Therapeutics's depreciation changed year-over-year?

Axsome Therapeutics's depreciation decreased by 22.1% year-over-year, from $149K to $116K.

What is the long-term trend for Axsome Therapeutics's depreciation?

Over 4 years (2021 to 2025), Axsome Therapeutics's depreciation has grown at a 60.4% compound annual growth rate (CAGR), from $76K to $503K.

Axsome Therapeutics AXSM Depreciation

Depreciation at other companies

AbbVieABBV

——

Jazz PharmaceuticalsJAZZ

——

AbbottABT

——

Other financials

Income statement

See full

Revenue$191.2M+57.4%

Gross profit$176.5M+58.0%

Operating income-$63.4M-11.2%

Net income-$64.5M-8.6%

EPS (diluted)-$1.26-3.3%

Balance sheet

See full

Cash & equivalents$305.1M+1.4%

Total debt$219.9M+4.1%

Total equity$54.6M+2.6%

Total assets$713.6M+19.6%

Cash flow

See full

Operating cash flow-$20.7M+52.3%

CapEx$121.0K-64.2%

Free cash flow-$20.8M+52.4%

Valuation

See full

Market cap$12.89B+52.0%

Enterprise value$12.81B+52.9%

P/S18.2×-1.4×

Profitability

See full

Gross margin92.6%+1.1pp

Operating margin-24.4%-9.3pp

Net margin-26.6%-9.8pp

FCF margin-10.2%-3.9pp

Returns & leverage

See full

Return on equity-349.4%+109pp

Debt / equity4×+0.1×

Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axsome Therapeutics's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Axsome Therapeutics's depreciation?: Axsome Therapeutics (AXSM) reported depreciation of $116K in Q1 2026.
How has Axsome Therapeutics's depreciation changed year-over-year?: Axsome Therapeutics's depreciation decreased by 22.1% year-over-year, from $149K to $116K.
What is the long-term trend for Axsome Therapeutics's depreciation?: Over 4 years (2021 to 2025), Axsome Therapeutics's depreciation has grown at a 60.4% compound annual growth rate (CAGR), from $76K to $503K.